400-815-1117
2026-01-15
International pharmaceutical leaders and investors gathered in San Francisco on Sunday to explore partnership opportunities with Chinese biotech companies, as the country's out-licensing deals exceeded $130 billion last year and its contribution to the global drug pipeline reached 30 percent.
國際制藥界領(lǐng)袖與投資者周日齊聚舊金山，探索與中國生物科技企業(yè)的合作機(jī)遇。去年中國醫(yī)藥對外授權(quán)交易額突破1300億美元，對全球創(chuàng)新藥研發(fā)管線貢獻(xiàn)度已達(dá)30%。
Organized by the Zhongguancun FIC Innovative Drug Strategic Development Alliance, the 2026 China FIC Innovation and Collaboration Summit served as a global roadshow and launch platform for key Chinese innovative drug projects, facilitating connections between Chinese pharmaceutical companies and international industry leaders while promoting increased multinational investment in China's biotech sector.
由ZFIC聯(lián)盟主辦的2026中國FIC創(chuàng)新與合作峰會，為中國重點(diǎn)創(chuàng)新藥項(xiàng)目提供了全球路演與發(fā)布平臺，促進(jìn)了中國藥企與國際產(chǎn)業(yè)領(lǐng)袖的對接，并推動(dòng)跨國資本加大對中國生物科技領(lǐng)域的投資。
"Our journey — from humble 'Me-Too' and 'Me-Better' to transformative 'First-in-Class' — tells a story not just of scientific progress, but of an entirely new ecosystem and a transformed model of global partnership," said the director-general of Beijing Investment Promotion Service Center during the summit."
我們正在從'Me too'和'Me better'到具有變革性的“First in class”轉(zhuǎn)變，這不僅是一個(gè)科學(xué)進(jìn)步的故事，更是一個(gè)全新生態(tài)系統(tǒng)和全球化合作模式轉(zhuǎn)型的故事。"北京市投資促進(jìn)服務(wù)中心主任在峰會中表示。
She called the event a "vital two-way bridge" that showcases China's potential to the world while connecting global expertise with Chinese innovation, and said that China's pharmaceutical sector momentum rests on several fundamental pillars.China's massive unified market, with over 1.4 billion people and healthcare coverage for 1.33 billion citizens, provides unparalleled scale for clinical development and commercialization of innovative medicines. The country's regulatory framework has evolved to operate in full compliance with International Council for Harmonisation guidelines, matching leading global standards while balancing innovation incentives with accessibility through volume-based procurement and national reimbursement negotiations, the director-general said.
她稱此次峰會為一座"至關(guān)重要的雙向橋梁"，既向世界展示中國潛力，又將全球?qū)I(yè)智慧與中國創(chuàng)新相連。她指出，中國醫(yī)藥行業(yè)的發(fā)展動(dòng)能基于幾大基石：中國擁有超過14億人口的龐大統(tǒng)一市場，其中13.3億公民享有醫(yī)療保障，為創(chuàng)新藥的臨床開發(fā)和商業(yè)化提供了無與倫比的規(guī)模優(yōu)勢；中國的監(jiān)管體系已全面遵循國際人用藥品注冊技術(shù)協(xié)調(diào)會指南，既對標(biāo)全球領(lǐng)先標(biāo)準(zhǔn)，又通過帶量采購和國家醫(yī)保談判在創(chuàng)新激勵(lì)與藥物可及性間取得平衡。
The pace of regulatory approvals has accelerated dramatically, with Chinese authorities approving a record 76 innovative drugs in 2025 alone. These streamlined review timelines have created clearer pathways for synchronized global drug development and launches, she said.
藥品審評審批速度已顯著加快，僅2025年中國就創(chuàng)紀(jì)錄地批準(zhǔn)了76款創(chuàng)新藥。這些簡化的審評時(shí)間線為全球同步研發(fā)和上市創(chuàng)造了更清晰的路徑。
China's emergence as a global research and development powerhouse is reflected in its out-licensing deals surpassing $130 billion last year, with approximately 30 percent of the worldwide innovative drug pipeline now being developed in China, according to the director.
中國作為全球研發(fā)強(qiáng)國的崛起，體現(xiàn)在去年對外授權(quán)交易額突破1300億美元，且全球約30%的創(chuàng)新藥研發(fā)管線來自中國。
Despite headwinds facing globalization and rising protectionism, Chinese Consul General in San Francisco Zhang Jianmin said that economic interdependence remains a global reality, with international collaboration essential for finding global solutions.
盡管面臨全球化逆風(fēng)和保護(hù)主義抬頭，中國駐舊金山總領(lǐng)事張建敏表示，經(jīng)濟(jì)相互依存仍是全球現(xiàn)實(shí)，國際合作對尋求全球性解決方案至關(guān)重要。
"The biopharmaceutical sector is a case in point, because this sector depends so much on global supply chains, cross-border clinical research, data sharing and the spirits of working together among scientists and innovators from around the world," Zhang said."Many of the tasks ahead of us are so complex that they are often beyond the capability of any individual country working alone. China and the United States are the two leading economies and the two leading innovators. If our two countries, our experts and scientists, our industries, are able to work together, it will immeasurably increase the chance of success in getting the most important job done," he said.
"生物制藥領(lǐng)域就是例證，該領(lǐng)域高度依賴全球供應(yīng)鏈、跨境臨床研究、數(shù)據(jù)共享以及全球科學(xué)家和創(chuàng)新者的協(xié)作精神。"他說，"我們面臨的許多任務(wù)如此復(fù)雜，往往超出任何單一國家獨(dú)立應(yīng)對的能力。中美作為兩大經(jīng)濟(jì)體和創(chuàng)新引領(lǐng)者，若兩國專家、科學(xué)家及產(chǎn)業(yè)界能攜手合作，將極大提升完成最重要任務(wù)的勝算。"
California State Treasurer Fiona Ma echoed this collaborative vision, highlighting the importance of leveraging technology to accelerate research and improve health outcomes. She said that California voters have consistently prioritized healthcare through statewide initiatives, approving bonds for stem cell research, children's hospitals and behavioral health services.
加州財(cái)長Fiona Ma呼應(yīng)了這一合作愿景，強(qiáng)調(diào)利用技術(shù)加速研究、改善健康成果的重要性。她指出加州選民始終通過全州倡議優(yōu)先保障醫(yī)療健康，批準(zhǔn)了用于干細(xì)胞研究、兒童醫(yī)院和行為健康服務(wù)的債券。
"So we have a lot of money now. We are investing in all of these areas. That's why we welcome the partnerships. We should not be doing research and development in our silos now. With the internet, with AI capabilities, we are better able to share our research," Ma said, "and that will expedite discoveries, increase people's health and longevity."
"因此我們現(xiàn)有充足資金正投入這些領(lǐng)域，這也是我們歡迎合作的原因。在互聯(lián)網(wǎng)和人工智能時(shí)代，我們不應(yīng)再固守孤島進(jìn)行研發(fā)，而應(yīng)更好地分享研究成果，這將加速科學(xué)發(fā)現(xiàn)，增進(jìn)人民健康與壽命。"
The summit highlighted China's decade-long transformation in pharmaceutical innovation. While the country's innovative drug pipeline has experienced explosive growth and become integral to the global pharmaceutical landscape, with 2025's cross-border licensing value doubling the previous year's scale, only a small percentage of China's new drug pipelines have been involved in transactions, indicating substantial untapped collaboration potential.
峰會凸顯了中國醫(yī)藥創(chuàng)新十年的轉(zhuǎn)型歷程。雖然中國創(chuàng)新藥管線呈爆炸式增長并已成為全球醫(yī)藥格局的重要組成部分，2025年跨境授權(quán)交易額更達(dá)上年規(guī)模兩倍，但其中僅小部分新藥管線參與交易，表明仍有巨大的合作潛力尚待開發(fā)。
The ZFIC Alliance designed the summit to address this gap by creating an efficient communication platform connecting international pharmaceutical companies, investment institutions and Chinese biotech enterprises. Nine representative projects were selected from nearly 30 roadshow applications for in-person pitching sessions, spanning multiple cutting-edge technology areas and designed to enhance international visibility and collaboration potential.
ZFIC聯(lián)盟舉辦此次峰會正是為了填補(bǔ)這一空白，構(gòu)建連接國際藥企、投資機(jī)構(gòu)與中國生物科技企業(yè)的高效溝通平臺。從近30個(gè)路演申請中精選的9個(gè)代表性項(xiàng)目進(jìn)行了現(xiàn)場推介，涵蓋多個(gè)前沿技術(shù)領(lǐng)域，旨在提升國際能見度與合作潛力。
Joseph Scheeren, a member of the French National Academy of Pharmacy with over three decades of pharmaceutical industry experience across the US, Europe and Asia, offered an optimistic assessment of China's trajectory.
擁有逾三十年橫跨美、歐、亞制藥行業(yè)經(jīng)驗(yàn)的法國國家藥學(xué)科學(xué)院院士Joseph Scheeren對中國發(fā)展路徑給予樂觀評價(jià)。
Read in CHINADAILY APP : US-China biotech summit builds bridges for innovative drug partners
